Published in NDT Plus on June 01, 2010
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med (1998) 1.81
A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. Transplantation (2009) 1.72
A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 1.29
Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ (2003) 1.12
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 1.09
Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg (2004) 1.04
Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med (2008) 1.03
Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy (2006) 1.02
Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation (2009) 0.99
Long-term kidney transplant survival. Am J Kidney Dis (2001) 0.99
Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol (2002) 0.96
Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol (1997) 0.92
Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. Nephrology (Carlton) (2008) 0.86
Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Transplant Proc (2004) 0.86
Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs (2003) 0.81
The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant (2009) 0.81
Induction antibody therapy in kidney transplantation. Am J Kidney Dis (2009) 0.81
Evolving trends in induction therapy. Transplant Rev (Orlando) (2009) 0.80
20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Transplantation (2008) 0.79
Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transpl Int (2008) 0.79
Immunosuppression use in renal transplantation from Asian transplant centers: a preliminary report from the Asian Transplant Registry. Transplant Proc (2004) 0.78
Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation. J Am Soc Nephrol (2009) 0.77
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol (2010) 3.01
Hyperinsulinemia and hyperfiltration in renal transplantation. Transplantation (2009) 2.06
A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. Transplantation (2009) 1.72
Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation (2006) 1.68
Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant (2008) 1.60
Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant (2012) 1.55
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant (2005) 1.50
Posttransplant Kaposi's sarcoma restricted to the site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus. Dermatology (2006) 1.46
Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int (2014) 1.43
Long-term consequences of uninephrectomy in male and female rats. Hypertension (2012) 1.42
Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus. Nefrologia (2012) 1.39
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant (2003) 1.39
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia (2013) 1.37
Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol (2006) 1.28
New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol (2006) 1.28
Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep (2009) 1.28
Trypanosoma cruzi I genotypes in different geographical regions and transmission cycles based on a microsatellite motif of the intergenic spacer of spliced-leader genes. Int J Parasitol (2010) 1.27
Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) (2003) 1.20
Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario. Transplantation (2003) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: a systematic review and meta-analysis. Liver Transpl (2012) 1.05
Multigene families in Trypanosoma cruzi and their role in infectivity. Infect Immun (2012) 1.01
Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr (2002) 1.01
Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white x C57BL/6)F(1)-bcl-2 transgenic mice. J Immunol (2004) 1.00
Cephalosporin-induced nonconvulsive status epilepticus: clinical and electroencephalographic features. Epilepsia (2005) 0.99
Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagn Microbiol Infect Dis (2004) 0.98
Glycogen phosphorylase in Acanthamoeba spp.: determining the role of the enzyme during the encystment process using RNA interference. Eukaryot Cell (2008) 0.96
Pleural effusion secondary to minoxidil in a peritoneal dialysis patient. Nephrol Dial Transplant (2004) 0.95
Return to dialysis after renal transplantation. Which would be the best way? Kidney Int Suppl (2002) 0.95
Differential expression and characterization of a member of the mucin-associated surface protein family secreted by Trypanosoma cruzi. Infect Immun (2011) 0.95
Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function. Am J Transplant (2004) 0.95
Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore) (2014) 0.94
Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant (2012) 0.94
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med (2011) 0.93
'Costa da Morte' ataxia is spinocerebellar ataxia 36: clinical and genetic characterization. Brain (2012) 0.92
Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin Pharmacol Toxicol (2005) 0.92
Parathyroidectomy in dialysis patients. Kidney Int Suppl (2002) 0.91
Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol (2002) 0.91
Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice. Nephrol Dial Transplant (2003) 0.90
Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation (2009) 0.89
Calreticulin-melatonin. An unexpected relationship. Eur J Biochem (2003) 0.89
Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant (2008) 0.89
Selection of a Bacillus pumilus strain highly active against Ceratitis capitata (Wiedemann) larvae. Appl Environ Microbiol (2009) 0.89
Fasciola hepatica: humoral and cytokine responses to a member of the saposin-like protein family following delivery as a DNA vaccine in mice. Exp Parasitol (2005) 0.88
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV. Clin Vaccine Immunol (2006) 0.88
New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) (2012) 0.88
Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. Diabetes Care (2012) 0.88
Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial. Transplantation (2003) 0.86
Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol (2012) 0.86
Microbiological profile of peritoneal dialysis peritonitis and predictors of hospitalization. Adv Perit Dial (2011) 0.86
Aggressive lung donor management increases graft procurement without increasing renal graft loss after transplantation. Clin Transplant (2012) 0.86
Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation (2011) 0.86
Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney Int Suppl (2008) 0.86
Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation (2008) 0.86
KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients. Clin Transplant (2011) 0.85
Is abdominal surgery still a contraindication for peritoneal dialysis? Nephrol Dial Transplant (2007) 0.85
Biochemical characterization and differential expression of a 16.5-kilodalton tegument-associated antigen from the liver fluke Fasciola hepatica. Clin Vaccine Immunol (2012) 0.85
Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant (2008) 0.85
Anticoccidial activity of maslinic acid against infection with Eimeria tenella in chickens. Parasitol Res (2010) 0.85
Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol (2008) 0.85
Effects of weight loss after biliopancreatic diversion on metabolism and cardiovascular profile. Obes Surg (2005) 0.84
Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl (2008) 0.84
Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol (2006) 0.84
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83
Pre- and postsurgical detection of IgG, IgM, and IgA specific to hydatidosis by ELISA with purified antigen enriched with the 5/B antigen complex. J Clin Lab Anal (2002) 0.83
Acute rejection in the elderly recipient: influence of age in the outcome of kidney transplantation. Int Urol Nephrol (2002) 0.83
Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother (2004) 0.83
Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors. Transplantation (2012) 0.83
The renal benefits of a healthy lifestyle. Kidney Int Suppl (2005) 0.83
Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension. Exp Physiol (2004) 0.82
Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension (2003) 0.82